A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO): NRG-BR008.
Reena S. Cecchini, Peter Y. Chen, Kimberly R. Gergelis, Hyejoo Kang et al.
Journal
Journal of Clinical Oncology
Topics
Lung Cancer Treatments and Mutations
article
A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO): NRG-BR008.
Reena S. Cecchini, Peter Y. Chen, Kimberly R. Gergelis, Hyejoo Kang, Eileen P. Connolly, Lior Z. Braunstein, Kelly L. Bolton, Erica Stringer-Reasor, Julia R. White, William M. Sikov, Atif J. Khan, Norman Wolmark, Hanna Bandos, Reshma Jagsi, Eleftherios P. Mamounas, Thomas B. Julian, Melissa P. Mitchell, Patricia A. Ganz, Shannon L. Puhalla
article en
Abstract
No abstract available for this paper.
Publication Tag
Journal of Clinical OncologyVol. 43(16_suppl)
Institutions
Allegheny Health Network (US), Memorial Sloan Kettering Cancer Center (US), The University of Texas MD Anderson Cancer Center (US), Emory University (US), University of Pittsburgh (US), Loyola University Chicago (US), Washington University in St. Louis (US), Brown University (US), Beaumont Health (US), Columbia University Irving Medical Center (US), UCLA Health (US), University of Rochester Medical Center (US), University of Alabama at Birmingham (US), Florida Hospital Cancer Institute (US), The University of Kansas Cancer Center (US), UPMC Hillman Cancer Center (US), University of Kansas Medical Center (US), Women & Infants Hospital of Rhode Island (US), NRG Oncology (US), NSABP Foundation (US), UCLA Jonsson Comprehensive Cancer Center